GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III study with mepolizumab, an interleukin 5 (IL-5) antagonist, in patients with severe hypereosinophilic syndrome (HES).
GSK announces new scholarships to recognise retiring CEO Sir Andrew Witty’s contribution to global health
- The Sir Andrew Witty GSK Scholarships will be funded by GSK and run by the London School of Hygiene & Tropical Medicine
- 10-year agreement to fund 30 scholars from sub-Saharan Africa on a Master of Science program
UK Biobank, GSK and Regeneron announce largest gene sequencing initiative on world’s most detailed health database to improve drug discovery and disease diagnosis
Groundbreaking UK/US initiative will deliver first data within a year.